График акции Protara Therapeutics, Inc.
Расширенный график
Простой график
О компании
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Подробнее| EBITDA | -0.0152 |
|---|---|
| Число акций ао | 0.01133 млрд |
| P/BV | 0.1895 |
| EV/EBITDA | 0.3262 |
| Цена ао | 4.15 |
| ISIN | US74365U1079 |
| Сайт | https://www.protaratx.com |
| Валюта | usd |
| IPO date | 2014-10-22 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| Изменение цены за день: | 0% (1.76) |
|---|---|
| Изменение цены за неделю: | -6.88% (1.89) |
| Изменение цены за месяц: | -7.37% (1.9) |
| Изменение цены за 3 месяца: | -15.79% (2.09) |
| Изменение цены за полгода: | -45.34% (3.22) |
| Изменение цены за год: | +0.5714% (1.75) |
| Изменение цены за 3 года: | -75.69% (7.24) |
| Изменение цены за 5 лет: | +450.17% (0.3199) |
| Изменение цены с начала года: | +21.38% (1.45) |
|
|
Недооценка
|
Эффективность
|
|||||||||||||||||||||||||||||||||||||
Дивиденды
|
Долг
|
Импульс роста
|
|||||||||||||||||||||||||||||||||||||
| Институционалы | Объем | Доля, % |
|---|---|---|
| Opaleye Management Inc. | 2692594 | 23.55 |
| Vanguard Group Inc | 427612 | 3.74 |
| Boxer Capital, LLC | 209227 | 1.83 |
| Baker Brothers Advisors, LLC | 199671 | 1.75 |
| Ikarian Capital, LLC | 188664 | 1.65 |
| Privium Fund Management (UK) Ltd | 119730 | 1.05 |
| Renaissance Technologies, LLC | 113300 | 0.99 |
| Geode Capital Management, LLC | 78518 | 0.69 |
| Bridgeway Capital Management, Inc. | 64000 | 0.56 |
| Citadel Advisors Llc | 38035 | 0.33 |
| ETF | Доля, % | Доходность за год, % | Дивиденды, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.00906 | 35.054312164247 | 1.54048 |
| Руководитель | Должность | Оплата | Год рождения |
|---|---|---|---|
| Mr. Jesse Shefferman | Co-founder, CEO, President & Director | 1.02M | 1972 (52 года) |
| Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. | Co-Founder, Senior VP & Chief Scientific Operations Officer | 694.16k | 1981 (43 года) |
| Mr. Patrick Fabbio M.B.A. | Chief Financial Officer | 696.62k | 1968 (56 лет) |
| Ms. Hannah Fry | VP, Principal Accounting Officer & Controller | N/A | 1991 (33 года) |
| Ms. Mary J. Grendell | General Counsel & Corporate Secretary | N/A | |
| Ms. Justine O'Malley | Senior Vice President of Investor Relations & Corporate Affairs |
Адрес: United States, New York. NY, 345 Park Avenue South - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.protaratx.com
Сайт: https://www.protaratx.com
